A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 21 Nov 2017 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.
- 21 Nov 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2022.
- 02 Aug 2016 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2019.